Blindness News and Research

RSS

TransTech Pharma to complete TTP054 Phase 2 trial on type 2 diabetes

TransTech Pharma, Inc., announced today that recruitment of patients for its recently initiated, multi-center Phase 2 clinical trial of TTP054 in type 2 diabetics, is exceeding expectations with initial top line results available in early 2013. The 90-day proof of concept study is being conducted in type 2 diabetics not well controlled with approved oral anti-diabetic agents.

2 Nov 2012

Inotek announces final data from trabodenoson Phase 2 trial on PAOG or ocular hypertension

Inotek Pharmaceuticals Corp., a leader in the development of innovative drug candidates to address significant diseases of the eye, today announced that final data from a Phase 2 clinical trial of trabodenoson, also known as INO-8875, in patients with primary open-angle glaucoma or ocular hypertension will be presented at the Ophthalmology Innovation Summit on Thursday, November 8, 2012 at the Chicago Marriott Downtown Magnificent Mile in Chicago, IL.

2 Nov 2012

FibroGen announces presentation of FG-4592 Phase 2 data on anemia at ASN Kidney Week 2012

FibroGen, Inc., today announced that two abstracts relating to FG-4592, its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) clinical candidate for the treatment of anemia in chronic kidney disease, have been accepted for oral and poster presentations at the American Society of Nephrology (ASN) Kidney Week 2012.

1 Nov 2012

Results of diabetes management program to be presented at Canadian Cardiovascular Congress

In Canada alone, almost 2 million people are known to be living with diabetes. And around a million more have the disease but are not aware of that fact, and have not been given the tools they need to control their blood sugar and safeguard their health.

29 Oct 2012

Ophthotech announces data from Fovista Phase 2b trial on wet AMD

Ophthotech Corporation today announced that data from a large, prospective, randomized, controlled Phase 2b clinical trial of Ophthotech's Fovista anti-PDGF therapy (1.5 mg) in patients with neovascular age-related macular degeneration (wet AMD) will be presented during Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting (AAO) on Sat., Nov. 10, 2012 at 9:15 a.m.

25 Oct 2012

Babies born to HIV positive mothers more likely to acquire measles

Non-infected babies born to HIV positive mothers should be vaccinated early against measles, to avoid them acquiring the virus or passing it on to others.

19 Oct 2012

Resverlogix commences RVX-208 Phase 2 trial in pre-diabetes mellitus

Resverlogix Corp. today announced that it has initiated an exploratory Phase 2 clinical trial in patients with pre-diabetes mellitus to examine the effects of RVX-208 and ApoA-I production on glucose metabolism.

17 Oct 2012

Antibiotic injections are associated with lower risk of infection in cataract surgery

Intracameral antibiotic injections were associated with a 22-fold reduction in the risk of postoperative infection following cataract surgery when compared with the standard post-operative treatment of antibiotic eyedrops, according to a Kaiser Permanente study.

16 Oct 2012

Comprehensive handbook on vitamin A deficiency disorders

Vitamin A plays a key role among the vitamins essential for healthy growth and development. Vitamin A deficiency disorders (VADD) are therefore an important part of general malnutrition that in the majority of cases leads to failure to thrive and underweight.

16 Oct 2012

Cigarette smoking may increase risk of age-related cataract

Cigarette smoking is a well-known risk factor for a wide-range of diseases. Now, scientists have evidence that smoking may also increase the risk of age-related cataract, the leading cause of blindness and vision loss in the world.

13 Oct 2012

Type 2 diabetes screening: an interview with Dr Simon Griffin, MRC Epidemiology Unit at Addenbrooke’s Hospital, Cambridge

Type 2 diabetes is a condition in which the body does not make sufficient insulin or the insulin it makes doesn’t work sufficiently well to maintain a normal level of blood glucose and so the blood glucose rises.

12 Oct 2012

NYSCF conference to discuss latest advances in stem cell research

Leaders in translational stem cell research from across the country and around the world will present findings on how advances in stem cell science lead to better treatments and cures to disease and injury at The New York Stem Cell Foundation's Seventh Annual Translational Stem Cell Research Conference, held at The Rockefeller University in Manhattan on October 10-11.

11 Oct 2012

New York Stem Cell Foundation names 6 scientists as 2012 NYSCF - Robertson Investigators

The New York Stem Cell Foundation (NYSCF) named six of the most promising scientists as its 2012 NYSCF - Robertson Investigators.

11 Oct 2012

New mechanism may alter principle understandings of molecular interactions within a cell's nucleus

Scientists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, with collaborators from Harvard University, the University of Madrid, Princeton University, and the University of Zurich, have discovered a new mechanism that may alter principle understandings of molecular interactions within a cell's nucleus.

11 Oct 2012

Mayo researchers discover new therapy for patients with neuromyelitis optica

Mayo Clinic researchers have identified a new therapy for patients with neuromyelitis optica that appears to stop inflammation of the eye nerves and spinal cord. NMO is a debilitating central nervous system disorder that is often misdiagnosed as multiple sclerosis (MS).

10 Oct 2012

Grp94 chaperone protein can interfere with clearance of myocilin from cells

The chaperone protein Grp94 can interfere with the clearance of another protein known to cause the glaucoma when mutated, a new study led by researchers at the University of South Florida has found. Using a cell model, the researchers also demonstrated that a new specific inhibitor of Grp94 facilitates clearance of the genetically-defective protein, called myocilin, from cells.

10 Oct 2012

Johns Hopkins Bloomberg School of Public Health epidemiologist receives Dean's Medal honor

Michael J. Klag, MD, MPH, dean of the Johns Hopkins Bloomberg School of Public Health, has awarded the Dean's Medal-the School's highest honor-to William Foege, MD, MPH. Foege is a celebrated epidemiologist and physician who played a leading role in many of the important public health campaigns of the past half-century, including efforts to eradicate smallpox and to control onchocerciasis (the cause of river blindness) and guinea worm.

8 Oct 2012

Government investment in eye examinations may boost the economy

Governments could add thousands of millions of dollars to the global economy simply by investing in eye examinations and the provision of glasses for some 703 million people who need them, according to a study published this month in the Bulletin of the World Health Organization.

6 Oct 2012

Patients with eye diseases can benefit from ArtCornea

Blindness is often caused by corneal diseases. The established treatment is a corneal transplant, but in many cases this is not possible and donor corneas are often hard to come by. In the future, an artificial cornea could make up for this deficiency and save the vision of those affected.

5 Oct 2012

Heavy caffeinated coffee consumption may increase risk of exfoliation glaucoma

A new study suggests caffeinated coffee drinkers should limit their intake to reduce their chances of developing vision loss or blindness. According to a scientific paper in Investigative Ophthalmology & Visual Science, heavy caffeinated coffee consumption is associated with an increased risk of developing exfoliation glaucoma, the leading cause of secondary glaucoma worldwide.

4 Oct 2012

Blindness News and Research

TransTech Pharma to complete TTP054 Phase 2 trial on type 2 diabetes

Inotek announces final data from trabodenoson Phase 2 trial on PAOG or ocular hypertension

FibroGen announces presentation of FG-4592 Phase 2 data on anemia at ASN Kidney Week 2012

Results of diabetes management program to be presented at Canadian Cardiovascular Congress

Ophthotech announces data from Fovista Phase 2b trial on wet AMD

Babies born to HIV positive mothers more likely to acquire measles

Resverlogix commences RVX-208 Phase 2 trial in pre-diabetes mellitus

Antibiotic injections are associated with lower risk of infection in cataract surgery

Comprehensive handbook on vitamin A deficiency disorders

Cigarette smoking may increase risk of age-related cataract

Type 2 diabetes screening: an interview with Dr Simon Griffin, MRC Epidemiology Unit at Addenbrooke’s Hospital, Cambridge

NYSCF conference to discuss latest advances in stem cell research

New York Stem Cell Foundation names 6 scientists as 2012 NYSCF - Robertson Investigators

New mechanism may alter principle understandings of molecular interactions within a cell's nucleus

Mayo researchers discover new therapy for patients with neuromyelitis optica

Grp94 chaperone protein can interfere with clearance of myocilin from cells

Johns Hopkins Bloomberg School of Public Health epidemiologist receives Dean's Medal honor

Government investment in eye examinations may boost the economy

Patients with eye diseases can benefit from ArtCornea

Heavy caffeinated coffee consumption may increase risk of exfoliation glaucoma

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News